Search Results

You are looking at 141 - 150 of 4,064 items for :

  • Refine by Access: All x
Clear All
Full access

Gastric Cancer Clinical Practice Guidelines

City of Hope Cancer Center

Gastric carcinoma is rampant in many countries around the world. An estimated 36,380 new cases of upper GI carcinomas and 25,120 deaths from these tumors will occur in the United States in 2005. These guidelines provide a systematic approach to gastric cancer and discuss advances in staging procedures such as laparoscopy and endoscopic ultrasonography and in possible functional imaging techniques. The guidelines also discuss the new standard in the United States: combination chemotherapy and radiotherapy in the adjuvant setting for a select group of patients.

For the most recent version of the guidelines, please visit

Full access

Attitudes Toward and Use of Cancer Management Guidelines in a National Sample of Medical Oncologists and Surgeons

Reshma Jagsi, Grace Huang, Kent Griffith, Brian J. Zikmund-Fisher, Nancy K. Janz, Jennifer J. Griggs, Steven J. Katz, and Sarah T. Hawley

grown more complex, guidelines have proliferated, 1 , 3 , 4 including those specifically pertaining to cancer management. 5 Scholars have devoted considerable attention to defining the optimal processes for guideline development and have investigated

Full access

Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score

Hsiao-Ching Huang, Gregory S. Calip, Jennifer Weiss, Yael Simons, V.K. Gadi, Oana C. Danciu, Garth H. Rauscher, and Kent F. Hoskins

Background The Oncotype 21-gene breast recurrence score (RS) is the most commonly ordered multigene breast cancer biomarker in the United States, 1 and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer base

Full access

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price

Daniel Tobias Michaeli and Thomas Michaeli

of the BTD in drug development and clinical practice by analyzing a uniquely large sample of 114 cancer drugs and 355 indications with FDA approval over 10 years. Breakthrough and nonbreakthrough cancer drugs and indications are compared regarding

Full access

Description of Venous Thromboembolism in Hospitalized Patients With Metastatic Cancer: A National Sample

Kahee A. Mohammed, Leslie Hinyard, Martin W. Schoen, Christian J. Geneus, Eric S. Armbrecht, Fred R. Buckhold, and Thomas E. Burroughs

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. 1 , 2 Patients with cancer and VTE have a lower survival rate; Sorensen et al 1 reported a 1-year survival rate of 12% in patients with VTE

Full access

Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers

Jeffrey W. Shevach, Danielle Candelieri-Surette, Julie A. Lynch, Rebecca A. Hubbard, Patrick R. Alba, Karen Glanz, Ravi B. Parikh, and Kara N. Maxwell

Background Pathogenic germline variants in high-risk cancer susceptibility genes carry implications for standard-of-care treatment options in patients with cancer 1 , 2 as well as identifying family members who have heritable risk of

Full access

How NCCN Guidelines Can Help Young Adults and Older Adolescents With Cancer and the Professionals Who Care for Them

Archie Bleyer

Background In this past spring of 2012, 2 new sets of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) were published directed at the adolescent and young adult (AYA) population with cancer: those for Adolescent and Young Adult

Full access

Anemia and Functional Disability in Older Adults With Cancer

Cynthia Owusu, Harvey Jay Cohen, Tao Feng, William Tew, Supriya G. Mohile, Heidi D. Klepin, Cary P. Gross, Ajeet Gajra, Stuart M. Lichtman, Arti Hurria, and on behalf of the Cancer and Aging Research Group (CARG)

rates of anemia among patients with cancer have been estimated to be much higher, with rates as high as 39% among older patients at enrollment in the European Cancer Anemia Survey 3 and 100% in patients with cancer undergoing chemotherapy. 4 The cause

Full access

Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic

Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis, and Karen E. Hoffman

An estimated 1 in 6 men in the United States will be diagnosed with prostate cancer in their lifetime. 1 Although progress has been made, much still needs to be done to improve the diagnosis, treatment, survival, and quality of life for this

Full access

Cervical Cancer Screening

Edward E. Partridge, Nadeem Abu-Rustum, Anna Giuliano, Stewart Massad, Joan McClure, Mary Dwyer, and Miranda Hughes

appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN: Continuing